Completed PHASE2 INTERVENTIONAL 3-arm NCT00429299

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer (CHERLOB)

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Breast

Interventions cyclophosphamide epidoxorubicin fluorouracil lapatinib paclitaxel trastuzumab

Updated 7 times since 2017 Last updated: Feb 22, 2016 Started: Aug 31, 2006 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00429299, this PHASE2 trial focuses on Neoplasms, Breast and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Brindisi, Italy , Candiolo (TO), Italy , Carpi (MO), Italy , Cremona, Italy , Forlì, Italy , Modena, Italy , Parma, Italy , Pavia, Italy , Perugia, Italy and 7 more locations